Epirus Biopharmaceuticals, Inc. (NASDAQ:EPRS)

CAPS Rating: 3 out of 5

A biopharmaceutical company pioneering the new field of synergistic combination pharmaceuticals, with a portfolio of product candidates in phase 2 clinical development.

Recs

2
Player Avatar thecyberguy (72.40) Submitted: 6/5/2008 2:37:32 PM : Underperform Start Price: $231.00 EPRS Score: +141.78

Who??

Member Avatar shazzan415 (< 20) Submitted: 1/4/2010 3:48:12 PM
Recs: 0

these guys just had a merger and named a new CEO ; At least two of the last companies the New CEO ran were sold to phizer. $0.84 is a deal
http://www.reuters.com/finance/stocks/keyDevelopments?rpc=66&symbol=CRXX.O&timestamp=20091221221600

Featured Broker Partners


Advertisement